Oxysterols in Metabolic Syndrome: From Bystander Molecules to Bioactive Lipids

Trends in Molecular Medicine

Volumn 22, Issue 7, 2016, Pages 594-614

  Guillemot Legris, Owein ^a   Mutemberezi, Valentin ^a   Muccioli, Giulio G ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

cytochrome; hydroxycholesterol; inflammation; LXR; obesity; ROR

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; CHEMOKINE RECEPTOR CXCR2; CHYLOMICRON; EPSTEIN BARR VIRUS INDUCED GENE 2 PROTEIN; ESTROGEN RECEPTOR ALPHA; INSULIN INDUCED GENE 1 PROTEIN; LIVER X RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYSTEROL; RETINOID RELATED ORPHAN RECEPTOR; SMOOTHENED RECEPTOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BYSTANDER EFFECT; CARDIOVASCULAR DISEASE; GENETIC MODEL; HUMAN; INFLAMMATION; METABOLIC REGULATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; ANIMAL; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; METABOLIC DISORDER; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; METABOLIC DISEASES; OXYSTEROLS;

EID: 84973517667     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.05.006     Document Type: Review

References (122)

1. 1 Brown, A.J., Jessup, W., Oxysterols: sources, cellular storage and metabolism, new insights into their roles in cholesterol homeostasis. Mol. Aspects Med. 30 (2009), 111–122.
2. 2 Iuliano, L., et al. Cholesterol metabolites exported from human brain. Steroids 99 (2015), 189–193.
3. 3 Ferguson, C.S., Tyndale, R.F., Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol. Sci. 32 (2011), 708–714.
4. 4 Ellero, S., et al. Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab. Dispos. 38 (2010), 679–686.
5. 5 Li, J., et al. De novo synthesis of steroids and oxysterols in adipocytes. J. Biol. Chem. 289 (2014), 747–764.
6. 6 Wang, H., et al. Liver X receptor alpha is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype. Mol. Cell Biol. 28 (2008), 2187–2200.
7. 7 Li, X., et al. Biosynthesis of the regulatory oxysterol, 5-cholesten-3β,25-diol 3-sulfate, in hepatocytes. J. Lipid Res. 48 (2007), 2587–2596.
8. 8 Janowski, B.A., et al. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 266–271.
9. 9 Hong, C., Tontonoz, P., Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13 (2014), 433–444.
10. 10 Wang, J., et al. Relative roles of ABCG5/ABCG8 in liver and intestine. J. Lipid Res. 56 (2015), 319–330.
11. 11 Jakobsson, T., et al. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci. 33 (2012), 394–404.
12. 12 Laffitte, B.A., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 5419–5424.
13. 13 Baranowski, M., et al. Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation. Cell. Physiol. Biochem. 33 (2014), 1047–1057.
14. 14 Ito, A., et al. LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. eLife, 4, 2015, e08009.
15. 15 Treuter, E., New wrestling rules of anti-inflammatory transrepression by oxysterol receptor LXR revealed. Cell Res. 21 (2011), 711–714.
16. 16 Wang, Y., et al. Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. 285 (2010), 5013–5025.
17. 17 Wang, Y., et al. A second class of nuclear receptors for oxysterols: regulation of RORα and RORγ activity by 24S-hydroxycholesterol (cerebrosterol). Biochim. Biophys. Acta 1801 (2010), 917–923.
18. 18 Jin, L., et al. Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORγ. Mol. Endocrinol. 24 (2010), 923–929.
19. 19 Soroosh, P., et al. Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 12163–12168.
20. 20 Lau, P., et al. The orphan nuclear receptor, RORα, regulates gene expression that controls lipid metabolism: staggerer (SG/SG) mice are resistant to diet-induced obesity. J. Biol. Chem. 283 (2008), 18411–18421.
21. 21 Kang, H.S., et al. Transcriptional profiling reveals a role for RORα in regulating gene expression in obesity-associated inflammation and hepatic steatosis. Physiol. Genomics 43 (2011), 818–828.
22. 22 Umetani, M., et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13 (2007), 1185–1192.
23. 23 Lappano, R., et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE, 6, 2011, e16631.
24. 24 Hevener, A.L., et al. Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome. Mol. Cell Endocrinol. 418:Pt 3 (2015), 306–321.
25. 25 Liu, S., et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58 (2009), 2292–2302.
26. 26 Gatto, D., et al. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity 31 (2009), 259–269.
27. 27 Preuss, I., et al. Transcriptional regulation and functional characterization of the oxysterol/EBI2 system in primary human macrophages. Biochem. Biophys. Res. Commun. 446 (2014), 663–668.
28. 28 Hannedouche, S., et al. Oxysterols direct immune cell migration via EBI2. Nature 475 (2011), 524–527.
29. 29 Liu, C., et al. Oxysterols direct B-cell migration through EBI2. Nature 475 (2011), 519–523.
30. 30 Raccosta, L., et al. The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J. Exp. Med. 210 (2013), 1711–1728.
31. 31 Briscoe, J., Therond, P.P., The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 14 (2013), 416–429.
32. 32 Nedelcu, D., et al. Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. Nat. Chem. Biol. 9 (2013), 557–564.
33. 33 Nachtergaele, S., et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat. Chem. Biol. 8 (2012), 211–220.
34. 34 Pospisilik, J.A., et al. Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell 140 (2010), 148–160.
35. 35 Teperino, R., et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 151 (2012), 414–426.
36. 36 Harada, K., et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazol e), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur. J. Pharmacol. 685 (2012), 59–69.
37. 37 Paul, S.M., et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J. Neurosci. 33 (2013), 17290–17300.
38. 38 Linsenbardt, A.J., et al. Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. Neuropharmacology 85 (2014), 232–242.
39. 39 Sun, M.Y., et al. Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices. J. Neurophysiol. 115 (2016), 1263–1272.
40. 40 Uner, A., et al. The role of GluN2A and GluN2B NMDA receptor subunits in AgRP and POMC neurons on body weight and glucose homeostasis. Mol. Metab. 4 (2015), 678–691.
41. 41 Radhakrishnan, A., et al. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 6511–6518.
42. 42 Ikonen, E., Cellular cholesterol trafficking and compartmentalization. Nat. Rev. Mol. Cell Biol. 9 (2008), 125–138.
43. 43 Bouchard, L., et al. Association of OSBPL11 gene polymorphisms with cardiovascular disease risk factors in obesity. Obesity (Silver Spring) 17 (2009), 1466–1472.
44. 44 Jelinek, D., et al. Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Hum. Mol. Genet. 20 (2011), 312–321.
45. 45 Nishimura, T., et al. Oxysterol-binding protein (OSBP) is required for the perinuclear localization of intra-Golgi v-SNAREs. Mol. Biol. Cell 24 (2013), 3534–3544.
46. 46 Kentala, H., et al. Sterol liganding of OSBP-related proteins (ORPs) regulates the subcellular distribution of ORP–VAPA complexes and their impacts on organelle structure. Steroids 99 (2015), 248–258.
47. 47 Calderon-Dominguez, M., et al. The StarD4 subfamily of steroidogenic acute regulatory-related lipid transfer (START) domain proteins: new players in cholesterol metabolism. Int. J. Biochem. Cell Biol. 49 (2014), 64–68.
48. 48 Yu, X.H., et al. NPC1, intracellular cholesterol trafficking and atherosclerosis. Clin. Chim. Acta 429 (2014), 69–75.
49. 49 Tremblay-Franco, M., et al. Effect of obesity and metabolic syndrome on plasma oxysterols and fatty acids in human. Steroids 99 (2015), 287–292.
50. 50 Guillemot-Legris, O., et al. Obesity is associated with changes in oxysterol metabolism and levels in mice liver, hypothalamus, adipose tissue and plasma. Sci. Rep., 6, 2016, 19694.
51. 51 Mutemberezi, V., et al. Development and validation of an HPLC-MS method for the simultaneous quantification of key oxysterols, endocannabinoids, and ceramides: variations in metabolic syndrome. Anal. Bioanal. Chem. 408 (2016), 733–745.
52. 52 Murakami, H., et al. Plasma oxysterols and tocopherol in patients with diabetes mellitus and hyperlipidemia. Lipids 35 (2000), 333–338.
53. 53 Bertolotti, M., et al. Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism. Nutr. Metab. Cardiovasc. Dis. 22 (2012), 823–830.
54. 54 Nunes, V.S., et al. Increased 27-hydroxycholesterol plasma level in men with low high density lipoprotein-cholesterol may circumvent their reduced cell cholesterol efflux rate. Clin. Chim. Acta 433 (2014), 169–173.
55. 55 Alkazemi, D., et al. Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J. Clin. Endocrinol. Metab. 93 (2008), 4282–4289.
56. 56 Suzuki, R., et al. Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab. 12 (2010), 567–579.
57. 57 Chen, S.J., et al. Relationships between inflammation, adiponectin, and oxidative stress in metabolic syndrome. PLoS ONE, 7, 2012, e45693.
58. 58 Kase, E.T., et al. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50 (2007), 2171–2180.
59. 59 Fernández-Veledo, S., et al. Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49 (2006), 3038–3048.
60. 60 Shirouchi, B., et al. 27-Hydroxycholesterol suppresses lipid accumulation by down-regulating lipogenic and adipogenic gene expression in 3T3-L1 cells. Cytotechnology, 2016, 10.1007/s10616-016-9962-5 Published online March 17, 2016.
61. 61 Hessvik, N.P., et al. The liver X receptor modulator 22(S)-hydroxycholesterol exerts cell-type specific effects on lipid and glucose metabolism. J. Steroid Biochem. Mol. Biol. 128 (2012), 154–164.
62. 62 Tranheim, K.E., et al. Dietary supplementation with 22-S-hydroxycholesterol to rats reduces body weight gain and the accumulation of liver triacylglycerol. Lipids 47 (2012), 483–493.
63. 63 Hilse, K.E., et al. The expression of UCP3 directly correlates to UCP1 abundance in brown adipose tissue. Biochim. Biophys. Acta 1857 (2016), 72–78.
64. 64 Virginio, V.W., et al. Arterial tissue and plasma concentration of enzymatic-driven oxysterols are associated with severe peripheral atherosclerotic disease and systemic inflammatory activity. Free Radic. Res. 49 (2015), 199–203.
65. 65 Upston, J.M., et al. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol. 160 (2002), 701–710.
66. 66 Hulten, L.M., et al. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J. Clin. Invest. 97 (1996), 461–468.
67. 67 Umetani, M., et al. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab. 20 (2014), 172–182.
68. 68 Kim, S.M., et al. 27-Hydroxycholesterol induces recruitment of monocytic cells by enhancing CCL2 production. Biochem. Biophys. Res. Commun. 442 (2013), 159–164.
69. 69 Shentu, T.P., et al. The role of oxysterols in control of endothelial stiffness. J. Lipid Res. 53 (2012), 1348–1358.
70. 70 Ikegami, T., et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J. Gastroenterol. 47 (2012), 1257–1266.
71. 71 Bieghs, V., et al. The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice. Gastroenterology 144 (2013), 167–178.
72. 72 Leonarduzzi, G., et al. Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic. Biol. Med. 39 (2005), 1152–1161.
73. 73 Kim, S.M., et al. 7α-Hydroxycholesterol induces inflammation by enhancing production of chemokine (C–C motif) ligand 2. Biochem. Biophys. Res. Commun. 467 (2015), 879–884.
74. 74 Buttari, B., et al. 7-Oxo-cholesterol potentiates pro-inflammatory signaling in human M1 and M2 macrophages. Biochem. Pharmacol. 86 (2013), 130–137.
75. 75 Sun, S., Liu, C., 7α, 25-Dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases. Front. Pharmacol., 6, 2015, 60.
76. 76 Yasuda, T., et al. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 22(R)-hydroxycholesterol requires de novo protein synthesis in activated macrophages. J. Steroid Biochem. Mol. Biol. 97 (2005), 376–383.
77. 77 Na, T.Y., et al. 22-S-Hydroxycholesterol protects against ethanol-induced liver injury by blocking the auto/paracrine activation of MCP-1 mediated by LXRα. J. Pathol. 235 (2015), 710–720.
78. 78 Reboldi, A., et al. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 345 (2014), 679–684.
79. 79 Korach-Andre, M., et al. Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E167–E178.
80. 80 Lau, P., et al. Rorα deficiency and decreased adiposity are associated with induction of thermogenic gene expression in subcutaneous white adipose and brown adipose tissue. Am. J. Physiol. Endocrinol. Metab. 308 (2015), E159–E171.
81. 81 Lau, P., et al. Homozygous staggerer (sg/sg) mice display improved insulin sensitivity and enhanced glucose uptake in skeletal muscle. Diabetologia 54 (2011), 1169–1180.
82. 82 Meissburger, B., et al. Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol. Med. 3 (2011), 637–651.
83. 83 Bryzgalova, G., et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 49 (2006), 588–597.
84. 84 Handgraaf, S., et al. Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable. Diabetes 62 (2013), 4098–4108.
85. 85 Meyre, D., et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat. Genet. 41 (2009), 157–159.
86. 86 Bambace, C., et al. NPC1 in human white adipose tissue and obesity. BMC Endocr. Disord., 13, 2013, 5.
87. 87 Fletcher, R., et al. The role of the Niemann–Pick disease, type C1 protein in adipocyte insulin action. PLoS ONE, 9, 2014, e95598.
88. 88 Zhou, T., et al. OSBP-related protein 8 (ORP8) regulates plasma and liver tissue lipid levels and interacts with the nucleoporin Nup62. PLoS ONE, 6, 2011, e21078.
89. 89 Li, T., et al. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52 (2010), 678–690.
90. 90 Erickson, S.K., et al. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44 (2003), 1001–1009.
91. 91 Repa, J.J., et al. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Reversal by cholic acid feeding. J. Biol. Chem. 275 (2000), 39685–39692.
92. 92 Li-Hawkins, J., et al. Disruption of the oxysterol 7α-hydroxylase gene in mice. J. Biol. Chem. 275 (2000), 16536–16542.
93. 93 Murphy, C., et al. Cholic acid as key regulator of cholesterol synthesis, intestinal absorption and hepatic storage in mice. Biochim. Biophys. Acta 1735 (2005), 167–175.
94. 94 Kojetin, D.J., Burris, T.P., REV-ERB and ROR nuclear receptors as drug targets. Nat. Rev. Drug Discov. 13 (2014), 197–216.
95. 95 Gao, M., Liu, D., The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance. AAPS J. 15 (2013), 258–266.
96. 96 Collins, J.L., et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45 (2002), 1963–1966.
97. 97 Briand, O., et al. Liver X receptor regulates triglyceride absorption through intestinal down-regulation of scavenger receptor class B, type 1. Gastroenterology 150 (2016), 650–658.
98. 98 Archer, A., et al. LXR activation by GW3965 alters fat tissue distribution and adipose tissue inflammation in ob/ob female mice. J. Lipid Res. 54 (2013), 1300–1311.
99. 99 Griffett, K., et al. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol. Metab. 4 (2015), 353–357.
100. 100 Chang, M.R., et al. Antiobesity effect of a small molecule repressor of RORγ. Mol. Pharmacol. 88 (2015), 48–56.
101. 101 Xu, L., et al. 5-Cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol. Pharmacol. 83 (2013), 648–658.
102. 102 Ren, S., et al. Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem. Biophys. Res. Commun. 360 (2007), 802–808.
103. 103 Bai, Q., et al. Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells. Atherosclerosis 214 (2011), 350–356.
104. 104 Bai, Q., et al. Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease. Metabolism 61 (2012), 836–845.
105. 105 Xu, L., et al. Regulation of hepatocyte lipid metabolism and inflammatory response by 25-hydroxycholesterol and 25-hydroxycholesterol-3-sulfate. Lipids 45 (2010), 821–832.
106. 106 Wahli, W., Michalik, L., PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol. Metab. 23 (2012), 351–363.
107. 107 Xu, L., et al. 25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages. Am. J. Physiol. Endocrinol. Metab. 302 (2012), E788–E799.
108. 108 Benned-Jensen, T., et al. Molecular characterization of oxysterol binding to the Epstein–Barr virus-induced gene 2 (GPR183). J. Biol. Chem. 287 (2012), 35470–35483.
109. 109 Ohgane, K., et al. Discovery of oxysterol-derived pharmacological chaperones for NPC1: implication for the existence of second sterol-binding site. Chem. Biol. 20 (2013), 391–402.
110. 110 Infante, R.E., et al. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 283 (2008), 1052–1063.
111. 111 Hynynen, R., et al. OSBP-related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism of neutral lipids. J. Lipid Res. 50 (2009), 1305–1315.
112. 112 Olkkonen, V.M., Li, S., Oxysterol-binding proteins: sterol and phosphoinositide sensors coordinating transport, signaling and metabolism. Prog. Lipid Res. 52 (2013), 529–538.
113. 113 Diczfalusy, U., et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J. Lipid Res. 50 (2009), 2258–2264.
114. 114 Gold, E.S., et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 10666–10671.
115. 115 Koarai, A., et al. 25-Hydroxycholesterol enhances cytokine release and Toll-like receptor 3 response in airway epithelial cells. Respir. Res., 13, 2012, 63.
116. 116 Englund, M.C., et al. 25-Hydroxycholesterol induces lipopolysaccharide-tolerance and decreases a lipopolysaccharide-induced TNF-alpha secretion in macrophages. Atherosclerosis 158 (2001), 61–71.
117. 117 Korach-Andre, M., et al. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 403–408.
118. 118 Beaven, S.W., et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab. 18 (2013), 106–117.
119. 119 Dib, L., et al. LXRα fuels fatty acid-stimulated oxygen consumption in white adipocytes. J. Lipid Res. 55 (2014), 247–257.
120. 120 Zhu, L., et al. Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity. Am. J. Physiol. Endocrinol. Metab. 306 (2014), E1188–E1197.
121. 121 Matic, M., et al. Estrogen signalling and the metabolic syndrome: targeting the hepatic estrogen receptor alpha action. PLoS ONE, 8, 2013, e57458.
122. 122 Griffett, K., et al. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem. Biol. 8 (2013), 559–567.